TLDR:
- GLIX1 secures key U.S. patent, boosting BioLineRx’s solid tumor development plans.
- Expanded GLIX1 patent estate strengthens long-term strategy in aggressive solid tumors.
- Broad IP coverage positions GLIX1 for global growth across major cancer markets.
- Joint venture readies 2026 glioblastoma trial as GLIX1 advances toward clinic.
- New protections support GLIX1’s parallel expansion into multiple tumor pathways.
BioLineRx Ltd. (BLRX.TA) traded at US $3.21, down 5.31%, while the TA-listed share remained steady at 1.8000 with minimal movement.
BioLineRx Ltd., BLRX.TA
The stock shifted as Hemispherian reported a major intellectual property milestone that strengthens the GLIX1 program. This development positioned the joint venture for broader progress across solid tumor therapies.
USPTO Approval Expands Patent Protection for GLIX1
The U.S. Patent and Trademark Office issued a Notice of Allowance for a key GLIX1 patent. The patent covers the use of GLIX1 for cancers with limited cytidine deaminase expression, and this trait appears in most solid tumors. This approval extends exclusivity to 2040 and includes eligibility for further protection.
The notice secures commercial and clinical rights for GLIX1 across a large global market. The ruling supports long-term development plans, and it strengthens the foundation for upcoming studies. The expanded protection enhances the program’s ability to advance multiple tumor targets.
Corresponding international applications remain under review. These applications could widen the program’s reach and add protection in major regions. The combined IP estate now anchors a robust future path for GLIX1.
Growing Global Patent Estate Supports Solid Tumor Strategy
The newly approved U.S. patent adds to established protection across the United States, Europe and several additional countries. These protections include coverage for central nervous system cancers, including aggressive forms like glioblastoma. Each issued patent extends until at least 2040 with potential extensions.
Hemispherian holds a pending application for GLIX1 in combination with PARP inhibitors. This approach targets cancers that display homologous recombination proficiency, and these cancers represent a significant unmet need. If granted, protection would extend to 2044.
This broad estate allows the joint venture to explore treatment expansion beyond initial indications. The patent coverage supports new therapeutic strategies and strengthens competitive positioning. These elements collectively reinforce long-term program durability.
Joint Venture Advances Toward Clinical Milestones
The joint venture between Hemispherian and BioLineRx is preparing a Phase 1/2a trial for glioblastoma. The study is planned for the first quarter of 2026, and early development activities continue across the program. The updated IP position accelerates preparations for parallel evaluation in additional tumors.
GLIX1 functions as a TET2-activating molecule that modulates DNA damage response. Preclinical data show strong anti-cancer activity across several models, and these results inform upcoming clinical work. The profile supports clinical readiness as regulatory steps progress.
BioLineRx maintains a long-standing presence in oncology development. The company uses global partnerships to expand therapeutic pipelines and support clinical execution. The strengthened GLIX1 pathway now contributes a significant opportunity for future cancer treatments.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
